ES2561253T3 - Bacterias probióticas que tienen actividad antioxidante y uso de las mismas - Google Patents

Bacterias probióticas que tienen actividad antioxidante y uso de las mismas Download PDF

Info

Publication number
ES2561253T3
ES2561253T3 ES11719626.1T ES11719626T ES2561253T3 ES 2561253 T3 ES2561253 T3 ES 2561253T3 ES 11719626 T ES11719626 T ES 11719626T ES 2561253 T3 ES2561253 T3 ES 2561253T3
Authority
ES
Spain
Prior art keywords
novara
dsmz
italy
germany
deposited
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11719626.1T
Other languages
English (en)
Inventor
Giovanni Mogna
Gian Paolo Strozzi
Luca Mogna
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Probiotical SpA
Original Assignee
Probiotical SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Probiotical SpA filed Critical Probiotical SpA
Application granted granted Critical
Publication of ES2561253T3 publication Critical patent/ES2561253T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)

Abstract

Al menos una cepa bacteriana que tiene propiedades antioxidantes que pertenece a una especie seleccionada de entre: - Bifidobacterium lactis BS 05 (ID 1666) depositada por Probiotical SpA, Novara (Italia) en la DSMZ en Alemania el 13.10.2009 y que tiene el número de depósito DSM 23032, - Lactobacillus acidophilus LA 06 (ID 1683) depositada por Probiotical SpA, Novara (Italia) en la DSMZ en Alemania el 13.10.2009 y que tiene el número de depósito DSM 23033, y - Lactobacillus brevis LBR01 (ID 1685) depositada por Probiotical SpA, Novara (Italia) en la DSMZ en Alemania el 13.10.2009 y que tiene el número de depósito DSM 23034 para su uso en el tratamiento de estrés oxidativo.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9

Claims (1)

  1. imagen1
    imagen2
ES11719626.1T 2011-03-17 2011-03-17 Bacterias probióticas que tienen actividad antioxidante y uso de las mismas Active ES2561253T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2011/000561 WO2012123770A1 (en) 2011-03-17 2011-03-17 Probiotic bacteria having antioxidant activity and use thereof

Publications (1)

Publication Number Publication Date
ES2561253T3 true ES2561253T3 (es) 2016-02-25

Family

ID=44120141

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11719626.1T Active ES2561253T3 (es) 2011-03-17 2011-03-17 Bacterias probióticas que tienen actividad antioxidante y uso de las mismas

Country Status (10)

Country Link
US (1) US20140065116A1 (es)
EP (1) EP2685994B1 (es)
JP (1) JP2014508186A (es)
CN (1) CN103582486B (es)
BR (1) BR112013023600A2 (es)
DK (1) DK2685994T3 (es)
ES (1) ES2561253T3 (es)
PL (1) PL2685994T3 (es)
RU (1) RU2572698C2 (es)
WO (1) WO2012123770A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20110792A1 (it) 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri appartenenti al genere bifidobacterium per uso nel trattamento della ipercolesterolemia.
ITMI20110791A1 (it) 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri in grado di metabolizzare gli ossalati.
ITMI20110793A1 (it) 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri probiotici e composizione sinbiotica contenente gli stessi destinata alla alimentazione dei neonati.
ITMI20111718A1 (it) 2011-09-23 2013-03-24 Probiotical Spa Un materiale impermeabile alla umidita e allo ossigeno per confezionare prodotti dietetici, cosmetici e specialita medicinali.
US20160106789A1 (en) * 2013-03-14 2016-04-21 Gil NOFAR Inhibition of Neurodegenerative Disease by Grape Seed Extract, Green Tea Extract and Probiotic Bacteria
US20160030493A1 (en) * 2013-03-14 2016-02-04 Gil NOFAR Inhibition of Neurodegenerative Disease by Grape Seed Extract, Green Tea Extract and Probiotic Bacteria
ITMI20130793A1 (it) 2013-05-14 2014-11-15 Probiotical Spa Composizione comprendente batteri lattici per uso nel trattamento preventivo e/o curativo delle cistiti ricorrenti.
ES2526986B1 (es) * 2013-07-18 2015-11-02 Biopolis, S.L. Nueva cepa de Bifidobacterium animalis subsp. lactis CECT 8145 y su uso para el tratamiento y/o prevención de sobrepeso y obesidad y enfermedades asociadas
CN103961338B (zh) * 2014-04-03 2016-01-06 浙江大学 羟基酪醇在抗阿霉素心肌毒性中的应用及以羟基酪醇为主要活性成分的药物组合物
CN104172177A (zh) * 2014-06-11 2014-12-03 南通昊友食品添加剂有限公司 一种食品抗氧化剂的生产方法
CA2951739C (en) * 2014-07-01 2023-09-19 Tntgamble, Inc. Bi-layer dual release probiotic tablets
WO2016032000A1 (ja) * 2014-08-29 2016-03-03 わかもと製薬株式会社 乳酸菌含有組成物
CN104522833A (zh) * 2014-12-16 2015-04-22 镇江拜因诺生物科技有限公司 一种微生物食品抗氧化剂的制备方法
TWI788111B (zh) * 2015-01-02 2022-12-21 美商梅拉洛伊卡公司 多元補充品組成物
TWI829098B (zh) 2015-01-02 2024-01-11 美商梅拉洛伊卡公司 細菌組成物
US10137164B2 (en) 2015-01-02 2018-11-27 Melaleuca, Inc. Dietary supplement compositions
KR101806130B1 (ko) * 2015-05-07 2017-12-08 주식회사 다인소재 유산균발효분말과 허브 추출물을 유효성분으로 하는 육가공용 항균 및 항산화 조성물
EP3352774A4 (en) * 2015-09-23 2019-04-03 Reoxcyn, LLC FLAVONOID COMPOSITIONS AND METHODS OF USE
RU2617946C1 (ru) * 2015-11-24 2017-04-28 Автономная Некоммерческая Организация "Научно-Исследовательский Центр Биотехнологии Антибиотиков И Других Биологически Активных Веществ "Биоан" Штаммы Lactobacillus brevis и Lactobacillus rhamnosus с установленной последовательностью генома, синтезирующие глутатион и комплекс внутриклеточных антиоксидантов
CN106473148A (zh) * 2016-09-14 2017-03-08 吴卓蓉 一种复合益生菌组合物及其制备方法及应用
IT201700068000A1 (it) * 2017-06-19 2018-12-19 Probiotical Spa Composizione di batteri e/o loro derivati la cui attività biologica è stata specificatamente studiata per il miglioramento dello stato di salute differenziato per maschi e femmine
CN107593929A (zh) * 2017-10-13 2018-01-19 东北农业大学 一种含有双歧杆菌和嗜酸乳杆菌的抗氧化契达干酪及其制备方法
CN107595921A (zh) * 2017-10-24 2018-01-19 南昌大学 一种复合益生菌发酵的仙人掌果制剂及其在治疗口腔溃疡中的应用
TWI693026B (zh) * 2019-01-07 2020-05-11 大江生醫股份有限公司 黑色素材發酵物及其製備方法與其用於增加抗氧化活性及保護眼睛的用途
IT202000007690A1 (it) * 2020-04-09 2021-10-09 Probiotical Spa Uso di ceppi di batteri Lactobacillus plantarum e/o Lactobacillus pentosus nella riduzione di una quantità ingerita o accumulata di fosfonati nel microbiota umano
WO2023137199A1 (en) * 2022-01-13 2023-07-20 Amare Global Nutritional supplements and methods of nutritional supplementation affecting weight loss
CN115944085B (zh) * 2022-12-07 2024-08-09 山东奥博森生物药业股份有限公司 一种功能性益生菌组合物及定量添加装置

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3819838A (en) * 1970-08-04 1974-06-25 Bush Boake Allen Ltd Encapsulated flavoring composition
CH637297A5 (fr) * 1978-12-05 1983-07-29 Nestle Sa Microbille comprenant un microorganisme et son procede de fabrication.
US4670272A (en) * 1985-11-08 1987-06-02 Frito-Lay, Inc. Thermostable creme
CN1423528A (zh) * 2000-04-18 2003-06-11 雀巢制品公司 营养单元
CA2559596A1 (en) * 2003-03-13 2004-11-25 Universite De Moncton (Bureau De Soutien A L'innovation) Antioxidant producing bacterium and uses thereof
ATE289514T1 (de) * 2003-11-03 2005-03-15 Peter-Hansen Volkmann Vaginalpflegezusammensetzung
KR100661032B1 (ko) * 2005-04-19 2006-12-22 주식회사한국야쿠르트 간 기능 개선, 혈중 알코올 감소 및 항산화에 유효한조성물
EP2210505A1 (en) * 2009-01-27 2010-07-28 Nestec S.A. Composition comprising caftaric acid and/or derivatives thereof
IT1400821B1 (it) * 2009-03-09 2013-07-02 Probiotical Spa Sospensione oleosa contenente batteri probiotici per uso pediatrico

Also Published As

Publication number Publication date
CN103582486B (zh) 2016-11-16
CN103582486A (zh) 2014-02-12
EP2685994B1 (en) 2015-12-30
RU2572698C2 (ru) 2016-01-20
PL2685994T3 (pl) 2016-05-31
EP2685994A1 (en) 2014-01-22
DK2685994T3 (en) 2016-02-01
US20140065116A1 (en) 2014-03-06
JP2014508186A (ja) 2014-04-03
BR112013023600A2 (pt) 2017-03-01
RU2013144267A (ru) 2015-04-27
WO2012123770A1 (en) 2012-09-20

Similar Documents

Publication Publication Date Title
ES2561253T3 (es) Bacterias probióticas que tienen actividad antioxidante y uso de las mismas
ES2491619T3 (es) Uso de bacterias coliformes productoras de gas inhibidoras de lactobacilos aisladas a partir de lactantes afectados por cólicos
CL2011001939A1 (es) Uso de lactobacillus helveticus cncm i-4095 para apoyar la perdida de peso y/o mantenimiento del peso en humanos y/o animales, particularmente para tratar la obesidad y trastornos metabólicos; y microorganismo de la cepa de lactobacillus helveticus cncm i-4095.
CL2016001235A1 (es) Cepa bacteriana aislada del genero burkholderia y metabolitos plaguicidas derivados-formulaciones y usos (divisional solicitud 467-2014).
PH12015502416A1 (en) Bacterial strains having antimicrobial activity and biocontrol compositions comprising the same
AR085943A1 (es) Composicion antimicrobiana
CL2011001937A1 (es) Uso de la cepa de lactobacillus rhamnosus cncm i-4096 para apoyar la pérdida de peso y/o mantenimiento del peso en humanos y/o animales, específicamente para el tratamiento de la obesidad.
MX2016006708A (es) Composiciones bacterianas sinergicas y sus metodos de produccion y usos.
IN2012DN02463A (es)
AR112198A2 (es) Bacteria rhamnosus fermentum con actividad antifúngica
SE1550189A1 (en) Therapeutic and prophylactic composition produced by microbiota
MX2015006491A (es) Composiciones bacterianas sinergicas y metodos de produccion y uso de las mismas.
RS54919B1 (sr) Bakterija za upotrebu kao probiotik za nutritivne i medicinske primene
EP4014982A3 (en) Composition for inducing proliferation or accumulation of regulatory t cells
BR112013018626A2 (pt) probióticos em bebida de fruta
CL2011000891A1 (es) Uso de la cepa probiotica lactobacillus reuteri dsm17938 o una composicion nutricional que comprende una cepa bacteriana probiotica lactobacillus reuteri dsm17938 porque sirve para preparar un medicamento o una composicion nutricional util para reducir las alteraciones de sueño y/o mejorar la calidad del sueño o los patrones de sueño en humanos o animales.
GB2482536B (en) Expression of antibody or a fragment thereof in lactobacillus
PH12015500091A1 (en) Non-pathogenic f18 e.coli strain and use thereof
RU2013148473A (ru) Бактериальные штаммы, способные метаболизировать оксалаты
RS54478B1 (en) LACTOBACILLUS PLANTARUM MCC1 DSM 23881 ISOLATED MICRO-ORGANISM AND ITS USE
RS54837B1 (sr) Upotreba streptococcus salivarius u lečenju hroničnih infekcija respiratornog trakta
ES2482666B1 (es) Uso de la cepa CECT 7426 para provocar quorum quenching de la señal autoinductor-2 (AI-2)
CL2017001818A1 (es) Bacteria de ácido láctico y su uso para el tratamiento de mastitis
PL386175A1 (pl) Nowe szczepy bakteriofagów do leczenia zakażeń bakteryjnych, zwłaszcza szczepami bakterii lekoopornych rodzaju Enterococcus
UA113399C2 (xx) Штам непатогенної грамнегативної бактерії та його застосування в дерматології